BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35617291)

  • 1. Lncrna ANGPTL1-3 and its target microRNA-30a exhibit potency as biomarkers for bortezomib response and prognosis in multiple myeloma patients.
    Zhou F; Guo L
    Hematology; 2022 Dec; 27(1):596-602. PubMed ID: 35617291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by sponging miR-30a-3p to activate c-Maf expression.
    Nian F; Zhu J; Chang H
    Biochem Biophys Res Commun; 2019 Jul; 514(4):1140-1146. PubMed ID: 31103265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNA T-cell factor 7 in multiple myeloma: A potential biomarker for deteriorated clinical features and poor prognosis.
    Zhang C; Chu M; Fan Y; Wu L; Li Z; Ma X; Zhuang W
    J Clin Lab Anal; 2020 Sep; 34(9):e23400. PubMed ID: 32578294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline lncRNA PCAT1 high expression and its longitude increment during induction therapy predict worse prognosis in multiple myeloma patients.
    Zhao P; Zhao X
    J Clin Lab Anal; 2021 Nov; 35(11):e23924. PubMed ID: 34564896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long non-coding RNA ANRIL and its target microRNAs (microRNA-34a, microRNA-125a and microRNA-186) relate to risk stratification and prognosis in multiple myeloma.
    Yin Y; Yang W; Zhang L; Liu K; Luo Z
    Hematology; 2021 Dec; 26(1):160-169. PubMed ID: 33528317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
    Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
    Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA NEAT1 serves as a novel biomarker for treatment response and survival profiles via microRNA-125a in multiple myeloma.
    Yu H; Peng S; Chen X; Han S; Luo J
    J Clin Lab Anal; 2020 Sep; 34(9):e23399. PubMed ID: 32608537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circular RNA_0000190 and its target microRNA-767-5p are dysregulated, and they are related to risk stratification as well as prognosis in multiple myeloma patients.
    Xiang Y; Xu X; Yang B; Wu Z; Jiang R; Xie Y
    Ir J Med Sci; 2022 Apr; 191(2):671-679. PubMed ID: 33864191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNAs lnc-ANGPTL1-3:3 and lnc-GJA10-12:1 present as regulators of sentinel lymph node metastasis in breast cancer.
    Sun D; Zhong J; Wei W; Liu L; Liu J; Lin X
    Oncol Lett; 2020 Nov; 20(5):188. PubMed ID: 32952657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of NIMA related kinase 2 in multiple myeloma and its relevance with disease features and prognosis to bortezomib treatment.
    Gu X; Wang Z; Pan Q
    J Clin Pharm Ther; 2022 Oct; 47(10):1690-1697. PubMed ID: 36087032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulated circular RNAs are closely linked to multiple myeloma prognosis, with circ_0026652 predicting bortezomib‑based treatment response and survival via the microRNA‑608‑mediated Wnt/β‑catenin pathway.
    Li L; Liu J; Du J; Jiang H; He H; Lu J; Qiang W; Hou N; Guo P; Zhuang Y; Fu W
    Oncol Rep; 2022 Nov; 48(5):. PubMed ID: 36129153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.
    Che F; Ye X; Wang Y; Ma S; Wang X
    Eur J Pharmacol; 2021 Jan; 891():173752. PubMed ID: 33253679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma.
    Li X; Yang Y; Yi X
    Technol Cancer Res Treat; 2020; 19():1533033820936770. PubMed ID: 32799769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
    Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
    Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-146b overexpression associates with deteriorated clinical characteristics, increased International Staging System stage, cacoethic chromosome abnormality, and unfavorable prognosis in multiple myeloma patients.
    Bao Y; Wei M; Ji X
    J Clin Lab Anal; 2020 May; 34(5):e23168. PubMed ID: 31908003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
    Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma.
    Szudy-Szczyrek A; Mlak R; Mielnik M; Mazurek M; Chocholska S; Podgajna M; Szczyrek M; Homa-Mlak I; Małecka-Massalska T; Hus M
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. lncRNA transcription factor 7 is related to deteriorating clinical features and poor prognosis in multiple myeloma, and its knockdown suppresses disease progression by regulating the miR-203-mediated Jagged1-Notch1 signaling pathway.
    Liu H; Shen Y; Xu Y; Wang L; Zhang C; Jiang Y; Hong L; Huang H; Liu H
    Oncol Lett; 2021 May; 21(5):412. PubMed ID: 33841573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA NEAT1/microRNA-125a axis predicts increased major adverse cardiac and cerebrovascular event risk independently in patients with unprotected left main coronary artery disease underwent coronary artery bypass grafting.
    Liu H; Yan X; Yu J
    J Clin Lab Anal; 2020 Jul; 34(7):e23299. PubMed ID: 32185824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The correlation of long non-coding RNA intersectin 1-2 with disease risk, disease severity, inflammation, and prognosis of acute ischemic stroke.
    Zhang Y; Niu C
    J Clin Lab Anal; 2020 Feb; 34(2):e23053. PubMed ID: 31647141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.